Video: New drug for rheumatoid arthritis

  1. Transcript of: New drug for rheumatoid arthritis

    BRIAN WILLIAMS, anchor: There's health news tonight, some new hope for patients who suffer from rheumatoid arthritis . It's not nearly as common as osteoarthritis, but the symptoms are usually debilitating. And now a new drug may be able to help those who have tried other treatments without funding any relief. Our report from our chief science correspondent Robert Bazell .

    ROBERT BAZELL reporting: Michael Cohen , a former trader on the Chicago Commodities Exchange , is in constant pain from rheumatoid arthritis , an autoimmune disease that afflicts one and a half million Americans. Every treatment he's tried has failed.

    Mr. MICHAEL COHEN: I'm looking and hoping for that, you know, maybe that there's a miracle out there that takes these symptoms away.

    BAZELL: It may not be a miracle, but for the first time in a decade an FDA advisory committee today approved a new drug for rheumatoid arthritis , or RA , a pill from Pfizer called Tofacitinib . The FDA is expected to give final approval within months. RA afflicts three times as many women as men.

    Ms. KAREN BARKEY (Diagnosed Three Months Ago): At the beginning I think getting used to the medication was a little hard. It has some side effects.

    BAZELL: In the past, many patients were left severely disabled. Then biological drugs that target the specific causes of the disease, including Enbrel and Humira came on the market allowing many, but not all patients, to live normal lives. Thirty to 40 percent of patients like Cohen don't respond to the drugs that are currently available. The proposed new drug aims at a completely different target. The FDA panel decided that the dangers of the new drug, including an increased risk lymphoma and elevated cholesterol, were outweighed by the benefits.

    Dr. TED FIELDS (Hospital For Special Surgery): It would be very nice down the road to have another option for someone who's failed the other drugs.

    BAZELL: Cohen and many thousands like him are hoping the new drug will relieve their agony. Robert Bazell , NBC News, New York.

updated 5/9/2012 7:11:13 PM ET 2012-05-09T23:11:13

Federal health advisers said Wednesday that a first-of-a-kind drug from Pfizer appears to be safe and effective for patients with rheumatoid arthritis, though they recommended follow-up studies to gauge the pill's long-term side effects.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

The Food and Drug Administration's panel of arthritis experts voted 8-2 in favor of Pfizer's tofacitinib for patients who have not responded to one or more other drugs. The FDA is not required to follow the group's advice, though it often does. A final decision is expected in August.

Panelists said the drug could be an important option for patients, but voiced concern over reports of lymphoma and infection among patients taking the pill. Assessing the drug's role in those problems is difficult because patients with rheumatoid arthritis are already predisposed to a range of health problems, including cancer.

If approved, tofacitinib would be the first pill for rheumatoid arthritis from a new class of pain medications called JAK inhibitors. The drugs work by interfering with enzymes that contribute to the inflammation process that causes joint pain, particularly in the hands and feet.

Studies conducted by Pfizer showed patients improved 20 percent or more on a medical questionnaire that measures arthritis pain and symptoms. However, the FDA said the company's results were less conclusive on another measure: X-ray images tracking the rate of joint damage.

Despite that shortcoming, panelists said Pfizer's pill could be an important option for patients who haven't responded to other drugs or aren't comfortable with injectable medications.

"I voted yes because I would like to have this drug available for rheumatoid arthritis patients, given that we know a third of them will not respond to available therapies," said Dr. Maria Suarez-Almazor of the MD Anderson Cancer Center in Houston.

For more than a decade, rheumatoid arthritis has been treated with injectable drugs like Humira, which block a messaging protein related to inflammatory diseases. Humira and rival Enbrel were the 10th and 11th best-selling drugs in the U.S. last year, with combined sales of $7 billion, according to IMS Health. The drugs are also prescribed for psoriasis and other diseases of the immune system.

Rheumatoid arthritis occurs when the immune system attacks the body's own joints and tissue. It differs from traditional arthritis, which is caused by long-term deterioration of bones and joints.

The most common side effects of treatment with tofacitinib have included bronchitis, headache, infections, and gastrointestinal symptoms like nausea, vomiting, and diarrhea. More serious side effects include higher cholesterol levels and increased creatinine levels.

Tofacitinib is a key product in Pfizer's pipeline, following patent expirations on several blockbuster drugs, including the world's best-selling prescription medication, Lipitor. Pfizer is studying tofacitinib as a potential treatment for psoriasis, inflammatory bowel disease, and renal transplant.

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments